The U.S. Food and Drug Administration unveiled a revolutionary AI-powered tool on Monday, aimed at cutting down the lengthy review times for scientific data and new pharmaceutical applications.
Dubbed “VitaScan,” the tool has been under development for two years in partnership with MIT. It uses machine learning to sort through clinical trial data, flag anomalies, and provide rapid risk assessments reducing the average approval time by up to 30%, according to officials.
Also Read: “Trump’s College Transcript ‘Leaks’ Online - Americans React with Memes, Mockery, and Curiosity”
“This is a breakthrough for both innovation and public safety,” said FDA Commissioner Sarah Walsh. “It allows us to be faster without sacrificing rigor.”
Critics are cautiously optimistic, with watchdog groups warning about potential overreliance on algorithms in sensitive decision-making. However, many believe this is a step toward solving the drug backlog that grew dramatically after the pandemic.
Follow us on X @Dobblog1
No comments:
Post a Comment
Join the conversation by leaving a comment below. Keep it respectful, relevant, and on-topic - we love hearing from our readers!